Joint Study by Rosetta Genomics and NYU Langone Medical Center Identifies Potential microRNA Drug Target for Mesothelioma

REHOVOT, Israel & PHILADELPHIA–(BUSINESS WIRE)–Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announced today that the results of a joint study with the NYU Langone Medical Center were published on May 12th, 2010 in the online issue of The Journal of Biological Chemistry. The study “Pro-tumorigenic Effects of miR-31 Loss in Mesothelioma,” demonstrates the potential of miR-31 to be used for the development of new therapies against mesothelioma and other cancers. The study may be viewed online at: http://www.jbc.org/content/early/2010/05/12/jbc.M110.100354.full.pdf+html

In the study, cell lines derived from mesothelioma patients were found not to express miR-31, a microRNA that has recently been characterized as a suppressor of breast cancer metastases. Functional assessment of miR-31 activity revealed its ability to inhibit proliferation, migration, invasion, and clonogenicity of mesothelioma cells. Reintroduction of miR-31 suppressed cell cycle and inhibited expression of multiple factors involved in cooperative maintenance of DNA replication and cell cycle progression. (read more…)

Incoming search terms for this article:

• rosetta genomics reported the results of a joint study with the nyu langone medical center in the online issue of the journal of biological chemistry
• NYU miRNA
• breast cancer rosetta genomics
• rosetta mirna profiling
• rosetta genomics rna
• Rosetta Genomics Ltd miRNA Breast Cancer
• NYU Medical Center MIRNA CANCER ARRAY
• nyu genomics rosetta
• new york university langone genomics
• mirna profiling of mesothelioma and adenocarcinoma

Related posts:

1. La Jolla Institute to develop San Diego’s first center for RNAi genomics research
2. Rosetta Genomics Restructuring
3. Rosetta Genomics Announces Issuance of Additional U.S. Patent
4. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
5. Rosetta Genomics Receives New York State Clinical Laboratory Permit for Its First Generation microRNA Diagnostic Tests

Tagged as: mesothelioma, microrna, mir-31, mirna, Rosetta Genomics